{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:19:39Z","timestamp":1791821979583,"version":"4.3.4"},"reference-count":33,"publisher":"Korean Ophthalmological Society","issue":"3","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ekjo.org"],"crossmark-restriction":true},"short-container-title":["Korean J Ophthalmol"],"published-print":{"date-parts":[[2024,6,5]]},"abstract":"<jats:p>Purpose: To evaluate the efficacy of intravitreal brolucizumab in polyp regression of treatment-naive polypoidal choroidal vasculopathy (PCV) patients and its effect on 1-year treatment outcome.Methods: Medical records of 31 treatment-naive PCV patients, who received three monthly intravitreal brolucizumab injections followed by as-needed injections for at least a year, were retrospectively reviewed. Visual and anatomical outcomes were evaluated at 3, 6, and 12 months. Complete polyp regression rate and percentage change of vascular lesion and polyp area were evaluated after three monthly injections of brolucizumab. The effect of complete polyp regression and the impact of vascular lesion and polyp reduction rate on 1-year treatment outcome were also evaluated.Results: In terms of visual outcome, best-corrected visual acuity significantly improved after 12-month follow-up (&lt;i&gt;p&lt;\/i&gt; &lt; 0.001). In terms of anatomical outcome, central macular thickness (CMT) and central choroidal thickness significantly decreased after 12-month follow-up (&lt;i&gt;p&lt;\/i&gt; &lt; 0.001). Complete polyp regression was observed in 23 patients (74.2%) after three monthly injections. Group with complete polyp regression had a higher rate of achieving dry macula at 3 months (&lt;i&gt;p&lt;\/i&gt; = 0.026) and fewer number of injections (&lt;i&gt;p&lt;\/i&gt; &lt; 0.001) compared to the group without complete polyp regression. Higher polyp reduction rate was significantly associated with higher CMT change from baseline at 3 months (&lt;i&gt;p&lt;\/i&gt; = 0.048) while higher vascular lesion reduction rate was significantly associated with higher CMT change from baseline at 12 months (&lt;i&gt;p&lt;\/i&gt; = 0.031) and fewer number of injections (&lt;i&gt;p&lt;\/i&gt; = 0.012).Conclusions: Intravitreal brolucizumab injection effectively improved visual and anatomical outcomes and achieved significant polyp regression in treatment-naive PCV patients. Complete polyp regression and the reduction rate of vascular lesion size and polyp size after loading injection significantly influence the treatment outcome of PCV patients. However, careful monitoring and preoperative warning is warranted due to occurrence of brolucizumab-related IOI.<\/jats:p>","DOI":"10.3341\/kjo.2023.0145","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T06:30:07Z","timestamp":1712557807000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.3341\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy of Brolucizumab in Polyp Regression of Treatment-Naive Polypoidal Choroidal Vasculopathy and Its Effect on 1-Year Treatment Outcome"],"prefix":"10.3341","volume":"38","author":[{"given":"Seung Hun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Song","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Woo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1893","reference":[{"key":"ref1","first-page":"1","volume-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV). 1990","author":"Yannuzzi","year":"2012"},{"key":"ref2","first-page":"443","volume-title":"Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup","author":"Cheung","year":"2021"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.10.1392"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.10.001"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46235-3"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-007-0498-2"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109\/09286580902999413"},{"key":"ref8","first-page":"639","volume-title":"Polypoidal choroidal vasculopathy: natural history","author":"Uyama","year":"2002"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01231-9"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.12.031"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"ref12","first-page":"89","volume-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","author":"Dugel","year":"2021"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.06.009"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00904-4"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52448-y"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0061-8"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-014-0349-x"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12216-2"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2023.0030"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-023-00999-4"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/iae.0000000000002583"},{"key":"ref22","first-page":"1497","volume-title":"Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy","author":"Kim","year":"2016"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86014-7"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-017-3718-6"},{"key":"ref25","first-page":"1569","volume-title":"Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: the Fujisan Study","author":"Gomi","year":"2015"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305076"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.4030"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-016-3467-y"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-022-00922-3"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091164"},{"key":"ref31","first-page":"8195","volume-title":"One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization","author":"Matsumoto","year":"2022"},{"key":"ref32","first-page":"379","volume-title":"Impact of polyp regression on 2-year outcomes of intravitreal aflibercept injections: a treat-and-extend regimen for polypoidal choroidal vasculopathy","author":"Morizane-Hosokawa","year":"2018"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.01.002"}],"container-title":["Korean Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.ekjo.org\/upload\/pdf\/kjo-2023-0145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.ekjo.org\/journal\/view.php?doi=10.3341\/kjo.2023.0145","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.ekjo.org\/upload\/pdf\/kjo-2023-0145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T08:09:33Z","timestamp":1718093373000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ekjo.org\/journal\/view.php?doi=10.3341\/kjo.2023.0145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.3341\/kjo.2023.0145","relation":{},"ISSN":["1011-8942","2092-9382"],"issn-type":[{"value":"1011-8942","type":"print"},{"value":"2092-9382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"2023-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-08","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-05","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}